Vencerx Therapeutics ring the changes appointing ex-Pfizer Director as CEO
Vencerx Therapeutics, a biotech focused on developing treatments for neurodevelopmental disorders, has announced the appointment of Robert Ring as CEO. Ring joins the biotech after having numerous roles within neurological areas, in a career that has spanned from drug development to patient advocacy.
Most notably, Ring held the role of Senior Director of Pfizer’s Autism Research Unit before leaving to join Autism Speaks as its CSO. In this latter role, he oversaw $300 million of funding invested into the autism research community. During this period, he oversaw the launch of MSSNG, a partnership with Google, now named Verily, and the Hospital for Sick Children. This allowed the creation of a database of genomic sequence information from 10,000 individuals with autism and their families.
“I am absolutely thrilled to be joining the team at Vencerx at a moment in time when the field of therapeutics development for rare neurodevelopmental disorders like Fragile X is poised to take off,” said Dr. Ring, on his appointment. “The past decade of CNS drug development field has quietly ignored what I see as a massive opportunity to address the diverse unmet needs of families across the autism and neurodevelopmental disorder communities by leveraging the rich diversity of targets and clinical assets pursued, and in many cases abandoned, for other indications.”
Explaining the decision to appoint Ring to the role of CEO, founder of Vencerx said: “Rob is a recognized leader in the field of autism research and brings years of experience working at the forefront of therapeutics development for related neurodevelopmental disorders such as Fragile X. We are pleased to have someone with Rob’s experience spearheading our efforts to advance treatments for Fragile X Syndrome and related conditions”.